MSD’s anti-TL1A mAb from $10.8bn acquisition wins in Phase III trial Clinical Trials Arena 11:47 Tue, 23 Jun
Merck Expands TL1A Lead With Positive Tulisokibart Results In UC Scrip Pharma Intelligence 20:52 Mon, 22 Jun